ALAR PHARMACEUTICALS INC.

Highlights Alar Pharmaceuticals Inc.

Equities

6785

TW0006785009

End-of-day quote Taipei Exchange Other stock markets 23:00:00 11/06/2024 BST			5-day change	1st Jan Change
254 ^TWD	-0.59%		-6.27%	+21.24%

05-10	Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-14	Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Alar Pharmaceuticals Inc. Has Received Notice of Allowance for Patent in Taiwan	03-07	CI
Alar Pharmaceuticals Inc. Approves Dividend Distribution for the Year Ended December 31, 2023, Payable on June 28, 2024	03-06	CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from United States Patent and Trademark Office	02-22	CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Japan Patent Office	02-22	CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Instituto Mexicano De La Propiedad Industrial	02-19	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals	11/10/23	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	03/03/23	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	11/08/22	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	23/03/22	CI
Alar Pharmaceuticals Inc. Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000	12/01/22	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	13/08/21	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	25/03/21	CI
Alar Presents Positive Interim Results of Long-Acting Buprenorphine Injectable in Opioid Dependent Patients	09/03/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW